Alembic Pharmaceuticals Ltd Q1 FY27 Earnings Call Summary

Revenue

Margin

Demand

Guidance

Tone

Metrics raised 3

FY27 US generics growth guidance raised to mid-to-high teens (from low-to-mid teens)
FY27 consolidated revenue growth guidance raised to closer to mid-teens (from low double-digit)
FY27 API business growth guidance raised to above 10% (prior guidance not stated but implied lower)

Tuesday, August 4, 2026 5:30 PM IST

Event Participants

Executives

3 Pranav Amin, G. Krishnan, Isha Lamba

Analysts

7 Chirag Dagli, Damayanti Kerai, Eshita Jain, Parth Sodha, Poonam Parekh, Rahul Jeewani, Rashmi Shetty

Financials & KPIs

Metric	Reported	Commentary
Consolidated Revenue	₹2,150 crore	+26% YoY, broad-based growth across all businesses
India Branded Business Growth	+7% YoY	Animal health +24% (22% of India revenue); human health lagging market, management targeting turnaround in 1-2 quarters
International Generics Growth	+37% YoY	Volume-led, supported by new launches and manufacturing utilization
US Generics Growth	+49% YoY (₹ terms)	~37-38% constant currency; ex-bosutinib ~25%; ~10% currency tailwind
API Business Growth	+33% YoY	Volume-led despite ongoing market pricing pressure
EBITDA	₹348 crore (16% margin)	+21% YoY; absorbed planned R&D and US branded investments
R&D Expenditure	₹186 crore (9% of revenue)	Driven by peptide development, exhibit batches, higher regulatory filings
Profit Before Tax	₹223 crore	+17% YoY, better operating leverage across business
Profit After Tax	₹173 crore	+12% YoY; effective tax rate 22% vs 19% due to new tax regime migration
Gross Debt	~₹1,600 crore	Higher on receivables from increased sales; expected to unwind to ~1x debt levels
Launches/Filings/Approvals	7 launches, 4 ANDAs filed, 10 approvals	US: ~15 more launches planned for rest of FY27

Geographic & Segment Commentary

India Branded: Grew 7% YoY; animal health (22% of India revenue) delivered 24% growth, while specialty therapies (gynae, gastro, ophthal — ~60% of India revenue) are tracking market growth. Human health lagged overall, dragging performance; new Sales & Marketing Head Ramesh Juneja leading grassroots fixes with positive trends expected within 1-2 quarters. FY27 India guidance: high single-digit, bridging gap to market growth.
US Generics: Revenue grew 49% YoY (reported), predominantly volume-driven; bosutinib (180-day exclusivity on 100mg/500mg strengths, launched June) contributed only one month of sales. Ex-bosutinib base grew ~25%, with base now ~$75-76 million/quarter. Seven products launched in Q1, with 15 more expected across remaining quarters; exclusivity on bosutinib runs till November.
Ex-US (RoW) Markets: Continued strong performance across markets; guided 15% growth in INR terms for FY27. Strategic expansion ongoing — new Latin American territories opened, JV in Saudi Arabia and Canada entry in progress. Mix of B2B partner-led and direct B2C opportunities.
API Business: 33% YoY growth in Q1, volume-led despite market pressure; FY27 guidance raised to grow above 10% level. Management noted solvent price pressure (Middle East-related) impacting gross margins.
US Branded Specialty: PIVYA soft launch completed Q1 with good reception; two additional complementary women's health products (UTI franchise) recently licensed. Pure-play branding model (CMO-sourced, no manufacturing capex); investments limited to field force and marketing. Expect breakeven trend by end FY27, positive contribution from FY28.

Company-Specific & Strategic Commentary

US Branded Platform Build: PIVYA plus two newly-licensed complementary women's health products form a UTI-focused specialty franchise; investment is entirely field force and marketing spend (no hardware/manufacturing), expected J-curve revenue ramp with funding ~150 bps margin dilution in FY27.
Management Restructuring: Ramesh Juneja appointed Sales & Marketing Head for Human Health; focus on prescription quality, prescriber base consolidation, field productivity, and chronic portfolio building.
Capacity & Pipeline Investments: Ophthalmic line debottlenecked (expanded capacity without incremental capex, though Q1 shutdown caused cost under-absorption); peptide development program progressing; ~₹400 crore capex added in FY26 supporting future operating leverage.
International Expansion: Saudi Arabia JV, Canada entry, and new Latin American territories — RoW expected to sustain double-digit growth over next 3-4 years.

Guidance & Outlook

Metric	Guidance / Outlook	Commentary
US Generics Growth	Mid-to-high teens for FY27 (raised from low-to-mid teens)	Driven by Q1 momentum, launch outlook (15 more launches), volume trends; subject to normal market conditions
Consolidated Revenue Growth	Closer to mid-teens for FY27 (raised from low double-digit)	Improved outlook driven by US strength, not changes to investment agenda
API Business Growth	Above 10% for FY27	Q1 strong at 33%; sustained volume-led momentum expected
India Business Growth	High single-digit, aligned closer to market growth	Bridging gap from FY26; specialised therapy areas tracking market, human health turnaround in 1-2 quarters
Ex-US Markets Growth	~15% in INR terms	Guidance maintained with high conviction (only guide what 100% achievable)
EBITDA Margin	~16% FY26 base; core margin to high teens, ~150 bps dilution from US branded	Net flattish to slightly better YoY; trajectory depends on US branded ramp (breakeven by Q4 vs next year)
US Branded Specialty	Breakeven trend by Q4 FY27, positive contribution from FY28	J-curve ramp — sales accelerate toward year-end

Risks & Constraints

Risk	Context
US Pricing Erosion	Persistent pricing pressure in US generics environment; management noted growth is volume-driven, and base business sustainability depends on offsetting erosion with 15+ launches annually. Exclusivity products face "drastic" volume impact post-competition.
Bosutinib Exclusivity Expiry	180-day exclusivity runs till November; volumes are small but pricing attractive. A second incumbent may enter on a different strength; post-exclusivity competition could sharply impact sales. Management cannot guide beyond November.
Gross Margin Dilution	Solvent price increases (Middle East conflict), product mix, and Q1 ophthalmic line maintenance shutdown caused under-absorption; margins remain within 70-75% guided range but pressure continued in Q1.
Working Capital / Debt	Gross debt at ~₹1,600 crore, elevated on receivables from higher sales; management expects unwinding in Q2-Q3 back to March levels, targeting ~1x debt-to-EBITDA. Interest cost expected to moderate.
India Human Health Execution	Acute and certain divisions dragging India growth; remedy is grassroots territory-level fixes under new leadership — visible improvement only expected in 1-2 quarters.
GST/Tax Regime Change	Migration to new tax regime raised effective tax rate from ~19% to ~22%, impacting PAT growth (12% vs PBT 17%) — a structural headwind now in base.
Regulatory & Geopolitical	Regulatory expectations and geopolitical uncertainties (Middle East, supply chains) cited as external risks; management believes execution quality and portfolio choices are key differentiators.

Q&A Highlights

US Generics Growth & Bosutinib Exclusivity

Question: Confirming 180-day exclusivity on bosutinib strengths drove Q1 US numbers? Ex-bosutinib growth drivers? (Damayanti Kerai, HSBC)
Answer: Confirmed exclusivity on 100mg and 500mg strengths. Ex-bosutinib, US grew closer to 25%, driven by Q4/Q1 launches capturing share. ~15 more launches expected in remaining quarters. Bosutinib contributed only one month (June launch) with small volumes but good pricing; exclusivity secured till November, after which competition could be drastic given low volumes. (Pranav Amin)

US Base Business Sustainability

Question: Is the ~$75-76 million quarterly base the new normal? (Chirag Dagli, DSP Mutual Funds)
Answer: Management hopes so but flagged balance between momentum and price erosion; trend should continue for next 1-2 quarters at least. Bosutinib exclusivity certainty only till November; a second player on the other strength may enter. (Pranav Amin)

US Branded Platform Investment & Payback

Question: What investment scale and timeline to positive contribution for US branded? (Damayanti Kerai, HSBC)
Answer: Pure play branding — only field force and marketing costs, no manufacturing/infrastructure (CMO-sourced). Revenue will scale in J-curve fashion; investments for Q1-Q2, sales pick up toward year-end. Breakeven trend by end FY27, positive contribution from FY28 onwards. Two complementary UTI products licensed to strengthen women's health franchise. (Pranav Amin)

EBITDA Margin Trajectory FY27

Question: With raised top-line guidance, what margin trajectory while investments continue? High teens possible? (Damayanti Kerai, HSBC; Rahul Jeewani, IIFL)
Answer: ~150 bps dilution from US branded for FY27 (unchanged guidance). Core business operating leverage is playing out — core margins improving to high teens, offset by US branded dilution, net flattish to slightly better than FY26's 16%. Exact landing depends on US branded breakeven timing (Q4 vs next year) — "a few percentage points here and there directionally." (G. Krishnan)

Gross Margin Drivers

Question: Gross margins flat QoQ despite bosutinib — what's happening? (Chirag Dagli, DSP Mutual Funds)
Answer: Within 70-75% guided range. Three factors: (1) solvent price increases from Middle East issue, (2) product mix, (3) Q1 preventive debottlenecking/maintenance shutdown on ophthalmic line causing cost under-absorption — capacity now expanded without incremental capex. (G. Krishnan)

India Business Structure & Human Health Turnaround

Question: Animal health now bigger than acute? When will human formulations growth pick up? (Chirag Dagli, DSP; Rahul Jeewani, IIFL; Rashmi Shetty, Dolat)
Answer: Correction — animal health is 22% of India revenue, acute ~37%, specialty ~60%. Gynae, gastro, ophthal tracking market; acute (cough/cold, Azithral) traction improving. Under new leadership (Ramesh Juneja), grassroots territory fixes underway — positive trends expected within 1-2 quarters. India full-year guidance: high single-digit, bridging gap to market growth. (Pranav Amin, G. Krishnan)

Depreciation & Intangibles

Question: Sharp increase in depreciation — what's driving it? (Chirag Dagli, DSP Mutual Funds)
Answer: Primarily amortization of intangible assets from US branded product acquisitions, capitalized in Q4 (life ~7-8 years), plus ~₹400 crore FY26 capex. ~70-75% of the QoQ depreciation increase is from intangibles; exact amortization figure shared offline. (G. Krishnan)

Working Capital / Debt Outlook

Question: Interest cost up — what's gross debt vs March and outlook? (Rashmi Shetty, Dolat Capital)
Answer: Gross debt ~₹1,600 crore, up from March purely on receivables from higher sales; should unwind in Q2-Q3 back to March levels, targeting ~1x debt. Interest rates also reduced, partially offsetting higher debt. Expect finance costs to moderate through the year. (G. Krishnan)

RoW Growth & Sustainability

Question: Which geographies contribute most and where's the incremental opportunity? (Parth Sodha, Trinetra)
Answer: RoW consistently growing double-digit; new territories (Latin America) opened, Saudi JV and Canada entry in progress. Mix of B2B partner-led and direct B2C opportunities; expect continued strong growth over next 3-4 years. (Pranav Amin)

US Growth in USD Terms

Question: Can you quantify US sales in USD? (Eshita Jain, Motilal Oswal)
Answer: Don't break out USD; currency impact ~10% YoY, so constant currency growth ~37-38%. Rupee depreciation supports pricing — reported growth of 49% reflects both. (G. Krishnan)

FY28 Outlook & API Guidance

Question: Beyond FY27, ex-bosutinib, will US still grow? (Rashmi Shetty, Dolat Capital)
Answer: US growth requires meaningful launches — 15 more this year, similar number next year, plus branded business contributing from FY28; expect FY28 growth over FY27. API guidance of 10%+ for FY27 stands, with Q1 at 33% suggesting comfortable beat. (Pranav Amin)

Key Takeaway

Alembic delivered a strong Q1 FY27 with consolidated revenue of ₹2,150 crore (+26% YoY), led by US generics (+49% reported, ~38% constant currency), API (+33%), and international generics (+37%), with India branded lagging at +7% awaiting a turnaround under new sales leadership. EBITDA grew 21% to ₹348 crore (16% margin), absorbing R&D of ₹186 crore (9% of revenue) and US branded platform investments, while PAT growth of 12% was dampened by a higher tax rate post new-regime migration. Management raised FY27 guidance: US generics now mid-to-high teens (from low-to-mid teens) and consolidated growth closer to mid-teens, driven by 15 further US launches, bosutinib exclusivity till November, and sustained volume momentum. Strategic priorities remain intact — peptide development, US branded specialty (PIVYA plus two complementary UTI products targeting breakeven by Q4 FY27 and positive contribution from FY28), and expanded RoW footprint via Saudi JV and Canada. Watch points include post-November bosutinib competition, US pricing erosion, working-capital-driven debt of ~₹1,600 crore, and the pace of India human health recovery.